{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=8", "query": { "condition": "Skin Diseases, Genetic", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1834, "total_pages": 184, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T03:16:39.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07603401", "title": "Expanded Access Program of Bitopertin For Participants With EPP or XLP", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Erythropoietic Protoporphyria (EPP)", "X-Linked Protoporphyria (XLP)" ], "interventions": [ { "name": "DISC-1459", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Disc Medicine, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 7, "location_summary": "Miami, Florida • Boston, Massachusetts • Detroit, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07603401" }, { "nct_id": "NCT01139957", "title": "Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Carcinoma", "Fallopian Tube Carcinoma", "Ovarian Neoplasm", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Evaluation of Cancer Risk Factors", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Study of High Risk Factors", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 1916, "start_date": "2010-06-07", "completion_date": "2020-04-10", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 141, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01139957" }, { "nct_id": "NCT03627767", "title": "Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis", "Dermatitis, Atopic", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1235, "start_date": "2018-06-11", "completion_date": "2020-10-07", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627767" }, { "nct_id": "NCT03979872", "title": "Risk Information and Skin-cancer Education for Undergraduate Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Young Adult" ], "interventions": [ { "name": "MC1R Genetic Testing", "type": "DIAGNOSTIC_TEST" }, { "name": "Skin Cancer Education", "type": "OTHER" }, { "name": "UV Photo", "type": "DEVICE" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER", "DEVICE" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2019-09-09", "completion_date": "2020-08-01", "has_results": true, "last_update_posted_date": "2021-07-13", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03979872" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT03529877", "title": "Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recessive Dystrophic Epidermolysis Bullosa" ], "interventions": [ { "name": "allo-APZ2-EB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "RHEACELL GmbH & Co. KG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "0 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-02-16", "completion_date": "2021-11-26", "has_results": false, "last_update_posted_date": "2022-10-07", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03529877" }, { "nct_id": "NCT02910011", "title": "Topical NanoDox® for Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Nanodox 1% (doxycycline monohydrate hydrogel)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2017-05-18", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-03-26", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 2, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02910011" }, { "nct_id": "NCT01822184", "title": "Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mucopolysaccharidosis (MPS)", "Hunter Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "MALE", "summary": "2 Years to 18 Years · Male only" }, "enrollment_count": 100, "start_date": "2013-01-18", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2021-03-17", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 3, "location_summary": "Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01822184" }, { "nct_id": "NCT05619900", "title": "Registry of Patients Diagnosed With Lysosomal Storage Diseases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mucopolysaccharidosis I", "Mucopolysaccharidosis II", "Mucopolysaccharidosis IV A", "Mucopolysaccharidosis VI", "Mucopolysaccharidosis VII", "Pompe Disease Infantile-Onset", "Neuronopathic Gaucher Disease", "Wolman Disease" ], "interventions": [ { "name": "There is no intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "ALL", "summary": "Up to 64 Years" }, "enrollment_count": 250, "start_date": "2022-05-31", "completion_date": "2050-05-31", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05619900" }, { "nct_id": "NCT00829829", "title": "PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intercritical Gout" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Rilonacept 80 mg", "type": "DRUG" }, { "name": "Rilonacept 160 mg", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 241, "start_date": "2009-02", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-18T03:16:39.839Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00829829" } ] }